NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

BACKGROUND: Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide greater improvements in asthma outcomes than currently approved biologics and standard-of-care therapies. Tezepelumab is a human m...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzies-Gow, Andrew, Colice, Gene, Griffiths, Janet M., Almqvist, Gun, Ponnarambil, Sandhia, Kaur, Primal, Ruberto, Gennaro, Bowen, Karin, Hellqvist, Åsa, Mo, May, Garcia Gil, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550847/
https://www.ncbi.nlm.nih.gov/pubmed/33050934
http://dx.doi.org/10.1186/s12931-020-01526-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550847/
https://www.ncbi.nlm.nih.gov/pubmed/33050934
http://dx.doi.org/10.1186/s12931-020-01526-6

Ejemplares similares